Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria

NCT ID: NCT01412437

Last Updated: 2014-12-17

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-30
• Study Completion Date: 2012-12-31

Brief Summary

The investigators will use different types of brain imaging (MRI) in patients with Phenylketonuria (PKU) who are currently not on a strict diet to test the hypothesis that there is improvement in brain circuitry and biochemistry after return to diet and/or sapropterin dihydrochloride (Kuvan).

Detailed Description

We plan to enroll 36 subjects with PKU. They will all be counseled to follow the PKU diet. They will be randomized to receive Kuvan. We will plan to enroll 12 in the diet alone group and 24 in the Kuvan group with the hope of 12 being responders (as defined by a 30% drop in blood phe levels). Those who do not have a blood response with decreased Phe will still be evaluated for a neurological response as measured by neurocognitive testing and neuroimaging as outlined in this protocol. All 24 in the Kuvan group will receive a 1 month trial of Kuvan and then the responders will have their insurance cover the drug and for the non responders Biomarin will supply Kuvan.

Aim 1: To test the hypothesis that stable patients with PKU who are not currently on diet have specific brain biomarkers quantifiable by DTI, fMRI and MRS and that the levels of these biomarkers correlate with the clinical severity and outcome. Our pilot study and the research of others have suggested the following as potential biomarkers for neural injury in PKU:

• Metabolic abnormalities: elevated Phe concentrations as measured by MRS.
• White matter microstructure: measured by apparent diffusion coefficient, (ADC), using DTI.
• Working memory and attention/executive function: measured by fMRI, Near infrared spectroscopy (NIRS) and neuropsychological testing.

We will study these potential biomarkers in a group of well characterized adults with PKU who are not currently on diet or a strict diet as evidenced by elevated Phe, but who were identified by the newborn screen and may have been on diet during childhood, with varying severity of clinical involvement.

Aim 2: To measure changes in biomarkers validated in Aim 1 after return to diet +/- Kuvan (sapropterin dihydrochloride; Kuvan)

Based on our preliminary data and that of others, Aim 1 should provide us with a number of candidate biomarkers for brain injury in PKU. We expect that these will include three types of markers that can be correlated: metabolic, structural and cognitive. We will use these biomarkers to study subjects during return to diet and/or initiation of Kuvan.

Aim 3: To compare cognitive performance in our subjects prior to and after return to diet +/- Kuvan. using the following tests:

Comprehensive Trail making test (CTMT) -Parts A and B Stroop WASI (IQ, digit span) BRIEF Edinburgh Handedness Inventory Hand Preference Demonstration Test

Outcome variables The primary endpoints in this study are 1) an estimate of the white matter damage (macroscopic and microscopic) in participants with PKU versus controls at baseline and after return to diet +/- Kuvan; 2) determination of a profile of brain biochemical abnormalities in participants with PKU versus controls at baseline and after return to diet/Kuvan, 3) assessment of cognitive and motor systems abnormalities (by fMRI and cognitive testing) in the participant cohort as compared to age matched typically developing non disease controls at baseline and after return to diet/Kuvan; 4) coefficient of variability of scoring on traditional neurocognitive.

After the conclusion of this study, future areas of research would include expansion to study long term effects of Kuvan, study of more impaired populations and response to Kuvan, and using optical imaging methods we are currently piloting in OTCD.

Method to investigate biomarkers of disease We plan to use 1HMRS to identify markers of disease severity such as elevations of Phe and decreases in NAA. This will be compared in participants and normal age matched controls. Additionally, diffusion tensor imaging will allow us to probe white matter fiber tracts that may be especially vulnerable in this disorder selectively. Lastly, fMRI may identify regions of differential activation in the brain that are different in participants versus age matched controls at rest and with a cognitive task probing working memory and attention.

Conditions

PKU

Keywords

PKU; MRI; neurocognition; sapropterin dihydrochloride

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Diet

12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise

Group Type: EXPERIMENTAL

diet

Intervention Type: DIETARY_SUPPLEMENT

12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise

sapropterin dihydrochloride

Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months

Group Type: EXPERIMENTAL

sapropterin dihydrochloride

Intervention Type: DRUG

20 mg/kg for 4 months

sapropterin dihydrochloride

Intervention Type: DRUG

Interventions

diet

12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise

Intervention Type: DIETARY_SUPPLEMENT

sapropterin dihydrochloride

20 mg/kg for 4 months

Intervention Type: DRUG

sapropterin dihydrochloride

Intervention Type: DRUG

Other Intervention Names

PKU diet; Biomarin Kuvan; Kuvan

Eligibility Criteria

Inclusion Criteria

1. Patients with PKU identified on Newborn screening and with phe concentration >12mg/dl on the newborn screen

2. Baseline phe level at study enrollment > 20 mg/dl (this is the level required for inclusion in the study, regardless of the level used to make diagnosis)

3. Age range: 18-45 years

4. Able to comply with neuroimaging without requiring sedation (typically requires IQ over 65). The IQ will be checked with the WASI (Weschler Adult scales of intelligence) before determining eligibility

5. Able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices)

6. Subject has ability to follow instructions in English

7. Female of childbearing age who is sexually active agrees to urine pregnancy test

8. Availability to come to Washington, DC to participate in this study

Exclusion Criteria

1. Age range <18 or >45 years

2. Inability to comply with neuroimaging without the use of sedation (low IQ or claustrophobic)

3. Presence of ferromagnetic device(s) that preclude safe imaging including cardiac pacemaker, neural pacemaker, surgical clips in the brain or blood vessels, surgically implanted metal plates, screws or pins, cochlear implants or metal objects in their body

4. Pregnant female or breastfeeding at screening or planning to become pregnant at any time during the study.

5. Baseline phe < 20 mg/dl

6. Currently on Kuvan

7. History of substance abuse

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Georgetown University

OTHER

Sponsor Role: collaborator

Children's National Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Andrea Gropman

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Andrea L Gropman, M.D.

Role: PRINCIPAL_INVESTIGATOR

Children's National Research Institute

Locations

Children's Research Institute

Washington D.C., District of Columbia, United States

Countries

United States

References

Christ SE, Moffitt AJ, Peck D. Disruption of prefrontal function and connectivity in individuals with phenylketonuria. Mol Genet Metab. 2010;99 Suppl 1:S33-40. doi: 10.1016/j.ymgme.2009.09.014.

Reference Type: BACKGROUND

PMID: 20123468 (View on PubMed)

Other Identifiers

BMRN 9956

Identifier Type: -

Identifier Source: org_study_id